Aligos Therapeutics to Announce 4th Quarter 2025 Financial Results on March 5, 2026
Rhea-AI Summary
Aligos Therapeutics (Nasdaq: ALGS) will report its fourth quarter 2025 financial results on Thursday, March 5, 2026 before the open of U.S. markets.
The company is a clinical-stage biotechnology firm focused on therapies for liver and viral diseases; timing and format details for the release were announced on Feb. 26, 2026.
Positive
- None.
Negative
- None.
News Market Reaction – ALGS
On the day this news was published, ALGS gained 8.07%, reflecting a notable positive market reaction. Argus tracked a trough of -5.3% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $3M to the company's valuation, bringing the market cap to $45M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Among key biotech peers, several names such as CVM and BYSI show single-day declines while ACET is modestly higher, but momentum data only flags ACET moving down and no broad synchronized move, supporting a stock-specific setup for ALGS.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 23 | Clinical data update | Positive | +2.1% | Positive CROI data for HBV programs and PK data for ALG-097558. |
| Jan 30 | Inducement grants | Neutral | -0.6% | Equity inducement awards of 81,100 options to new employees. |
| Jan 21 | Phase 2 study update | Neutral | -0.1% | B-SUPREME Phase 2 enrollment and interim analysis timeline update. |
| Jan 13 | Leadership appointment | Positive | +6.1% | Appointment of Chief Commercial Officer to build commercial capabilities. |
| Dec 12 | Inducement grants | Neutral | +15.5% | Stock option awards totaling 14,100 shares under inducement plan. |
Recent news has generally seen price moves that align with the underlying tone, with stronger reactions around leadership and corporate actions.
Over the last several months, Aligos has combined clinical progress with corporate and financing developments. Positive CROI data on pevifoscorvir and ALG-097558 on Feb 23, 2026 coincided with a modest +2.06% move. Leadership changes, including appointing a Chief Commercial Officer on Jan 13, 2026, saw a stronger +6.08% reaction. Inducement grants in Dec 2025 and Jan 2026 also moved the stock, while Phase 2 B-SUPREME updates in Jan 2026 had limited price impact. Today’s earnings-date announcement fits into this cadence of operational and corporate milestones.
Market Pulse Summary
The stock moved +8.1% in the session following this news. A strong positive reaction aligns with how ALGS has sometimes responded to milestones such as leadership appointments and prior clinical updates, which saw moves up to 15.51%. Investors would likely weigh this earnings-date news against existing fundamentals from the last 10-Q, including net loss and cash runway disclosures. Past alignment between news tone and price moves suggests enthusiasm can build but may remain sensitive to subsequent financing or clinical data updates.
AI-generated analysis. Not financial advice.
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it will report the Company’s fourth quarter 2025 financial results on Thursday, March 5, 2026, before the open of the U.S. financial markets.
About Aligos
Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biopharmaceutical company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D expertise to advance its purpose-built pipeline of therapeutics with high unmet medical needs such as chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronaviruses.
For more information, please visit www.aligos.com or follow us on LinkedIn or X.
Forward-Looking Statement
This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this press release that are not historical facts may be considered “forward-looking statements,” including without limitation, statements regarding Aligos’ mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Such forward-looking statements are subject to substantial risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties inherent in the drug development process, including Aligos’ clinical stage of development, the process of designing and conducting clinical trials and the regulatory approval processes. For a further description of the risks and uncertainties that could cause actual results to differ from those anticipated in these forward-looking statements, as well as risks relating to the business of Aligos in general, see Aligos’ Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 6, 2025 and its future periodic reports to be filed or submitted with the Securities and Exchange Commission. Except as required by law, Aligos undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, or to reflect the occurrence of unanticipated events.
Company
Jordyn Tarazi
Vice President, Investor Relations & Corporate Communications
(650) 910-0427
jtarazi@Aligos.com
FAQ
When will Aligos Therapeutics (ALGS) report Q4 2025 results?
What time will Aligos (ALGS) release its March 5, 2026 Q4 2025 report?
Will Aligos (ALGS) include clinical updates with the Q4 2025 financial release?
How can investors access Aligos (ALGS) Q4 2025 results on March 5, 2026?
Why does Aligos Therapeutics (ALGS) announce the Q4 2025 release date in advance?
